JP2020515523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515523A5 JP2020515523A5 JP2019541267A JP2019541267A JP2020515523A5 JP 2020515523 A5 JP2020515523 A5 JP 2020515523A5 JP 2019541267 A JP2019541267 A JP 2019541267A JP 2019541267 A JP2019541267 A JP 2019541267A JP 2020515523 A5 JP2020515523 A5 JP 2020515523A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- daily dose
- daily
- maximum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 86
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 30
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 20
- 229940109262 curcumin Drugs 0.000 claims 15
- 235000012754 curcumin Nutrition 0.000 claims 15
- 239000004148 curcumin Substances 0.000 claims 15
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 13
- 229960003105 metformin Drugs 0.000 claims 13
- 229960003712 propranolol Drugs 0.000 claims 10
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 7
- 229960000590 celecoxib Drugs 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 6
- 229960004601 aliskiren Drugs 0.000 claims 6
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 3
- 229960004773 losartan Drugs 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 2
- 229940075559 piperine Drugs 0.000 claims 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 2
- 235000019100 piperine Nutrition 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039476A JP2023075272A (ja) | 2017-01-31 | 2023-03-14 | ガン治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452479P | 2017-01-31 | 2017-01-31 | |
| US62/452,479 | 2017-01-31 | ||
| PCT/NZ2018/050006 WO2018143826A1 (en) | 2017-01-31 | 2018-01-31 | Cancer therapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039476A Division JP2023075272A (ja) | 2017-01-31 | 2023-03-14 | ガン治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515523A JP2020515523A (ja) | 2020-05-28 |
| JP2020515523A5 true JP2020515523A5 (enExample) | 2021-03-11 |
Family
ID=63040946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541267A Pending JP2020515523A (ja) | 2017-01-31 | 2018-01-31 | ガン治療 |
| JP2023039476A Pending JP2023075272A (ja) | 2017-01-31 | 2023-03-14 | ガン治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039476A Pending JP2023075272A (ja) | 2017-01-31 | 2023-03-14 | ガン治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200197335A1 (enExample) |
| EP (1) | EP3576746A4 (enExample) |
| JP (2) | JP2020515523A (enExample) |
| CN (1) | CN110494142A (enExample) |
| AU (2) | AU2018215857A1 (enExample) |
| CA (1) | CA3051840A1 (enExample) |
| WO (1) | WO2018143826A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020027665A1 (en) * | 2018-07-30 | 2020-02-06 | Gillies Mcindoe Research Institute | Novel pharmaceutical compositions for cancer therapy |
| WO2020135920A1 (en) * | 2018-12-28 | 2020-07-02 | Université Libre de Bruxelles | Kit for inhaled chemotherapy, and treatment of lung cancer with said kit |
| US20230090708A1 (en) * | 2020-01-29 | 2023-03-23 | Massey Ventures Limited | Methods and compositions for the treatment of hemangioma |
| US20240180852A1 (en) * | 2021-03-03 | 2024-06-06 | Signpath Pharma, Inc. | Treatment for malignant pleural effusion in humans |
| CN113069443A (zh) * | 2021-04-12 | 2021-07-06 | 四川大学 | 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077394A1 (en) * | 2004-02-11 | 2005-08-25 | Ramot At Tel-Aviv University Ltd | Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid |
| EP3164121A4 (en) * | 2014-07-01 | 2018-06-13 | Vicus Therapeutics, LLC | Combination drug therapies for cancer and methods of making and using them |
| KR20170040804A (ko) * | 2014-08-12 | 2017-04-13 | 길리스 맥킨도 리서치 인스티튜트 | 암 진단 및 치료법 |
| WO2016054511A1 (en) * | 2014-10-02 | 2016-04-07 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells |
-
2018
- 2018-01-31 JP JP2019541267A patent/JP2020515523A/ja active Pending
- 2018-01-31 AU AU2018215857A patent/AU2018215857A1/en not_active Abandoned
- 2018-01-31 WO PCT/NZ2018/050006 patent/WO2018143826A1/en not_active Ceased
- 2018-01-31 CA CA3051840A patent/CA3051840A1/en active Pending
- 2018-01-31 CN CN201880019933.1A patent/CN110494142A/zh active Pending
- 2018-01-31 US US16/482,056 patent/US20200197335A1/en not_active Abandoned
- 2018-01-31 EP EP18747771.6A patent/EP3576746A4/en not_active Withdrawn
-
2023
- 2023-03-14 JP JP2023039476A patent/JP2023075272A/ja active Pending
- 2023-05-22 US US18/200,251 patent/US20230364037A1/en not_active Abandoned
-
2024
- 2024-01-07 AU AU2024200098A patent/AU2024200098A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515523A5 (enExample) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2009102342A5 (enExample) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| JP2014526503A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| JP2011173928A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2016534063A5 (enExample) | ||
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| JP2009530413A5 (enExample) | ||
| JP2010530376A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2015532296A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP2021509395A5 (enExample) | ||
| JPWO2020175629A5 (enExample) | ||
| JP2018531273A5 (enExample) |